Repeated molecular testing, aligned with the 2021 WHO Classification of CNS tumors, revealed the presence of an IDH1 R132H mutation and the absence of 1p/19q co-deletion, leading to the reclassification of the tumor as astrocytoma, IDH-mutant, WHO Grade 4. The gene discussed is IDH1; the disease is central nervous system neoplasm.